Comparative Pharmacology
Head-to-head clinical analysis: IOMERVU versus RENOVIST II.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOMERVU versus RENOVIST II.
IOMERVU vs RENOVIST II
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiocontrast agent that attenuates X-rays by increasing radiopacity of blood vessels and tissues, allowing visualization during imaging procedures.
RENOVIST II is a radiographic contrast agent that contains diatrizoate meglumine and diatrizoate sodium. It increases the radiopacity of vascular structures and organs by attenuating X-rays due to the high atomic number of iodine atoms in the molecule.
Intravenous: 0.5-2 mL/kg of iomeprol 300-400 mg I/mL for imaging, not exceeding 200 mL total dose; arterial: up to 250 mL per procedure.
1-2 mL/kg IV bolus, not to exceed 150 mL total; may be repeated once if necessary.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In renal impairment, half-life is prolonged (up to 10-30 hours in severe impairment), necessitating dose adjustment and monitoring. The half-life is not significantly affected by hepatic impairment.
1.2 hours in patients with normal renal function; prolonged to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Iomeprol is almost exclusively eliminated via renal glomerular filtration, with 92-98% of the administered dose recovered unchanged in urine within 24 hours. Less than 2% is excreted in feces via biliary elimination. In patients with normal renal function, renal clearance approximates glomerular filtration rate.
Renal: 95% as unchanged drug via glomerular filtration; fecal: <5%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent